BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 6, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2003

View Archived Issues

Evidence of antiinflammatory effects for efalizumab in atopic asthma

Read More

Potential cognitive benefits suggested for donepezil and vitamin E in AD

Read More

Early response to antivirals predicts sustained response in chronic hepatitis C

Read More

Phase II laquinimod study for MS meets primary endpoint according to first analysis

Read More

Clofarabine enters pivotal European trial for ALL

Read More

Cerezyme approved for type 3 Gaucher's disease in E.U.

Read More

Genzyme completes acquisition of SangStat

Read More

Phase II program of ISIS-113715 follows encouraging phase I data

Read More

FDA approves expanded Synagis labeling for children with congenital heart disease

Read More

Medtronic acquires remaining rights to rhBMP-2

Read More

Roche and ParAllele form type 2 diabetes genetic collaboration

Read More

SBIR grant supports development of melanoma peptide vaccine

Read More

Genmab delivers antibody targeting IL-15 receptor to Amgen

Read More

Thymitaq studied in new phase I/II trial in combination with Taxotere

Read More

Lilly licenses Antares drug delivery technology

Read More

First dose level completed in phase Ib DVT trial of ThromboView

Read More

Acceptable safety profile described for NBI-3001 in recurrent malignant glioma

Read More

AstraZeneca claims novel KDR inhibitors for cancer and other disorders

Read More

Two series of piperidine-based antibacterial agents prepared and tested at GSK

Read More

New tripeptides with HCV NS3-inhibitory activity covered by Boehringer Ingelheim patent

Read More

Novo Nordisk and Boehringer Ingelheim present new histamine H3 modulators

Read More

Novel antitumor protein kinase inhibitors in early development at Vertex

Read More

Canadian scientists design new photosensitizers for cancer, ocular disorders, etc.

Read More

HARP antibiotics: a novel class for resistant Gram-positive infections

Read More

Potent and selective CCR5 antagonist for HIV highlighted by Pfizer at ICAAC

Read More

Orally bioavailable meropenem prodrugs designed by Japanese group

Read More

Aminomethylcycline antibiotic profiled at ICAAC meeting

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing